Remdesivir and COVID-19. - National Genomics Data Center (CNCB-NGDC)

Advanced Search

Remdesivir and COVID-19.

Lei-Yun Wang, Jia-Jia Cui, Qian-Ying Ouyang, Yan Zhan, Cheng-Xian Guo, Ji-Ye Yin

Author Information

Lei-Yun Wang: Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410078, China; Engineering Research Center of Applied Technology of Pharmacogenomics, Ministry of Education, Changsha, China; National Clinical Research Center for Geriatric Disorders, Changsha, Hunan, China.
Jia-Jia Cui: Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410078, China; Engineering Research Center of Applied Technology of Pharmacogenomics, Ministry of Education, Changsha, China; National Clinical Research Center for Geriatric Disorders, Changsha, Hunan, China.
Qian-Ying Ouyang: Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410078, China; Engineering Research Center of Applied Technology of Pharmacogenomics, Ministry of Education, Changsha, China; National Clinical Research Center for Geriatric Disorders, Changsha, Hunan, China.
Yan Zhan: Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410078, China; Engineering Research Center of Applied Technology of Pharmacogenomics, Ministry of Education, Changsha, China; National Clinical Research Center for Geriatric Disorders, Changsha, Hunan, China.
Cheng-Xian Guo: Center of Clinical Pharmacology, the Third Xiangya Hospital, Central South University, Changsha, China.
Ji-Ye Yin: Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410078, China; Engineering Research Center of Applied Technology of Pharmacogenomics, Ministry of Education, Changsha, China; National Clinical Research Center for Geriatric Disorders, Changsha, Hunan, China; Hunan Key Laboratory of Precise Diagnosis and Treatment of Gastrointestinal Tumor, Changsha, China. Electronic address: yinjiye@csu.edu.cn.

PMID: 33010833 DOI: 10.1016/S0140-6736(20)32019-5

No abstract text available.

Yi Chuan. 2020 Feb 20;42(2):212-221 [PMID: 32102777]
Lancet. 2020 May 16;395(10236):1569-1578 [PMID: 32423584]
Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082 [PMID: 29126136]
N Engl J Med. 2020 Sep 3;383(10):994 [PMID: 32649078]
Nature. 2020 May;581(7809):434-443 [PMID: 32461654]

Adenosine Monophosphate

Adult

Alanine

Betacoronavirus

COVID-19

Coronavirus Infections

Double-Blind Method

Humans

Pandemics

Pneumonia, Viral

SARS-CoV-2

COVID-19 Drug Treatment

remdesivir

Adenosine Monophosphate

Alanine

Letter Research Support, Non-U.S. Gov't Comment

Remdesivir and COVID-19.Remdesivir and COVID-19.Remdesivir and COVID-19.Remdesivir and COVID-19.Remdesivir for COVID-19.[Remdesivir for COVID-19].Remdesivir in covid-19.Remdesivir (Veklury) for COVID-19.Remdesivir and COVID-19 - Authors' reply.Inhaled remdesivir treatment for COVID-19.

Predictive Value of Comorbid Conditions for COVID-19 Mortality.Clinical evolution and mortality of critically ill patients with SARS-CoV-2 pneumonia treated with remdesivir in an adult intensive care unit of Paraguay.Natural Product-Based Screening for Lead Compounds Targeting SARS CoV-2 M.The pharmacogenomic landscape in the Chinese: An analytics of pharmacogenetic variants in 206,640 individuals.The CO Extract (Ze 339) Blocks SARS-CoV-2 Replication In Vitro.Unveiling the Antiviral Capabilities of Targeting Human Dihydroorotate Dehydrogenase against SARS-CoV-2.In silico analysis of SARS-CoV-2 proteins as targets for clinically available drugs.Assessment of the potential value of combining western medicine therapies with traditional chinese medicine in the treatment of COVID-19: Mechanistic perspectives.Current state-of-the-art and potential future therapeutic drugs against COVID-19.Xuanfei Baidu decoction in the treatment of coronavirus disease 2019 (COVID-19): Efficacy and potential mechanisms.

See all "Cited by" articles